At Viralgen, we're All-In AAV™. It’s all we do. This singular focus makes us proud to be known for one thing: Being a world leader in rAAV-based gene therapy manufacturing.

As an independently operated CDMO and subsidiary of AskBio, Viralgen delivers cGMP AAV manufacturing that scales with you – from early construct optimization to feasibility studies to full commercial campaigns.

We're built to scale your life-changing AAV-based gene therapies. Need proof? We have a 41-out-of-41 success ratio for IND/IMPD dossiers. And, we’ve built our business on foundational AAV science, housing the world's largest dedicated AAV manufacturing capacity for one reason: To get patients with genetic diseases closer to therapies that can make a life-changing – and sometimes life-saving – difference.

Ready to roll? | Schedule your next successful step now.